{
    "id": "dbpedia_8099_1",
    "rank": 30,
    "data": {
        "url": "https://www.merck.com/news/merck-and-simcere-sign-agreement-to-establish-pioneering-china-joint-venture/",
        "read_more_link": "",
        "language": "en",
        "title": "Merck and Simcere Sign Agreement to Establish Pioneering China Joint Venture",
        "top_image": "http://cts.businesswire.com/ct/CT?id=bwnews&sty=20120517006612r1&sid=sfsite1&distro=nx",
        "meta_img": "http://cts.businesswire.com/ct/CT?id=bwnews&sty=20120517006612r1&sid=sfsite1&distro=nx",
        "images": [
            "https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/site-logo.svg",
            "https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/search-white.svg",
            "https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/close.svg",
            "https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/burger-white.svg",
            "https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/close.svg",
            "https://www.merck.com/wp-content/uploads/sites/124/2020/03/B2-We-are-driven-by-a-shared-purpose-that-is-to_-Invent-for-Life.jpg?resize=486,432",
            "http://cts.businesswire.com/ct/CT?id=bwnews&sty=20120517006612r1&sid=sfsite1&distro=nx",
            "https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/news-release-opt-in-image-.png?resize=516,596",
            "https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/stories-rl-1-.png",
            "https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/stories-rl-2.png",
            "https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/stories-rl-3.png",
            "https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/twitter-brands.svg",
            "https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/facebook-f-brands.svg",
            "https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/linkedin-brands.svg",
            "https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/instagram-brands.svg",
            "https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/youtube-brands.svg",
            "https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/accessibility.png",
            "https://privacy-policy.truste.com/privacy-seal/seal?rid= ",
            "https://privacy-policy.truste.com/privacy-seal/seal?rid= "
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": "2011-07-21T17:00:00+00:00",
        "summary": "",
        "meta_description": "Partnership Focused on Providing Significantly Enhanced Access to Quality Medicines for Chinese Patients Merck & Co., Inc., Whitehouse Station, N.J., (NYSE:MRK), acting through an affiliate and known as MSD outside the United States and Canada, and China’s Simcere Pharmaceutical Group (NYSE:SCR, Simcere) today announced the signing of a framework agreement to establish a joint venture focused on serving China's rapidly expanding health care needs by providing significantly improved access to quality medicines in major therapeutic areas. The companies announced the partnership at a signing ceremony at Merck Research Laboratories in Rahway, N.J. with Mr. Richard T. Clark, Merck chairman, Mr. Adam Schechter, president, Merck Global Human Health, Mr. Michel Vounatsos, president, MSD in China, Mr. Jinsheng Ren, chairman and CEO of Simcere Pharmaceutical Group, and Dr. Yehong Zhang, president, Simcere Pharmaceutical Group. Mr. Zhijun Luo, secretary of China's Jiangsu Provincial",
        "meta_lang": "en",
        "meta_favicon": "https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/apple-touch-icon.png",
        "meta_site_name": "Merck.com",
        "canonical_link": "https://www.merck.com/news/merck-and-simcere-sign-agreement-to-establish-pioneering-china-joint-venture/",
        "text": "Partnership Focused on Providing Significantly Enhanced Access to Quality Medicines for Chinese Patients\n\nMerck & Co., Inc., Whitehouse Station, N.J., (NYSE:MRK), acting through\n\nan affiliate and known as MSD outside the United States and Canada, and\n\nChina’s Simcere Pharmaceutical Group (NYSE:SCR, Simcere) today announced\n\nthe signing of a framework agreement to establish a joint venture\n\nfocused on serving China’s rapidly expanding health care needs by\n\nproviding significantly improved access to quality medicines in major\n\ntherapeutic areas.\n\nThe companies announced the partnership at a signing ceremony at Merck\n\nResearch Laboratories in Rahway, N.J. with Mr. Richard T. Clark, Merck\n\nchairman, Mr. Adam Schechter, president, Merck Global Human Health, Mr.\n\nMichel Vounatsos, president, MSD in China, Mr. Jinsheng Ren, chairman\n\nand CEO of Simcere Pharmaceutical Group, and Dr. Yehong Zhang,\n\npresident, Simcere Pharmaceutical Group.\n\nMr. Zhijun Luo, secretary of China’s Jiangsu Provincial Committee,\n\npresided over the signing ceremony.\n\nThis novel and innovative partnership will combine the extensive\n\nresources and expertise of a global health care company and a leading\n\nChinese pharmaceutical company in support of Merck and Simcere’s goal of\n\nbuilding a strategic partnership with development, registration,\n\nmanufacturing and sales capabilities. The initial focus of the\n\npartnership will be branded pharmaceutical products for cardiovascular\n\nand metabolic diseases.\n\nSpecifically, in the area of cardiovascular disease, the partnership\n\nwill offer a combined portfolio of selected medicines from both\n\ncompanies, including ZOCOR® (simvastatin), COZAAR® (losartan) and\n\nRENITEC® (enalapril) by Merck/MSD, and XINTA (levamlodipine) and\n\nSHUFUTAN (rosuvastatin) by Simcere. In the metabolic disease area, the\n\npartnership will work to maximize access in China to sitagliptin, a\n\nDPP-IV inhibitor for the treatment of type 2 diabetes. Type 2 diabetes\n\nis increasingly recognized as a significant public health threat in\n\nChina.\n\n“Merck is proud to partner with Simcere, one of China’s leading\n\npharmaceutical companies and an organization that shares Merck’s\n\ncommitment to enhancing health care in China,” said Mr. Schechter. “This\n\npartnership is another step forward in Merck’s strategy to grow our\n\nbusiness in China and is fully aligned with the Chinese government’s\n\ngoal to increase access to quality products.”\n\n“Today marks another key milestone in Simcere’s ongoing quest to better\n\nthe lives of our patients through innovative medicines,” said Mr. Ren.\n\n“This innovative partnership seeks to address the enormous challenges of\n\nthe Chinese healthcare system and address the needs of Chinese patients\n\nand health care stakeholders.”\n\n“This partnership between Simcere and Merck is not only strategically\n\nsignificant for both organizations, but also a landmark event for\n\nJiangsu’s biopharmaceutical industry,” said Mr. Luo. “Biopharmaceuticals\n\nis an emerging industry of strategic importance for Jiangsu Province and\n\nthis partnership will bring additional momentum to the development of\n\nthis industry. It will help Jiangsu in providing more quality\n\npharmaceuticals to China and the world.”\n\nThe establishment of this joint venture is subject to satisfying certain\n\nagreed to closing conditions.\n\nAbout Simcere Pharmaceutical Group\n\nSimcere Pharmaceutical Group (NYSE:SCR, Simcere) is a leading\n\npharmaceutical company specializing in development, manufacturing, and\n\nmarketing of branded generic and proprietary pharmaceuticals in China.\n\nIn recent years, Simcere has been focusing its strategy on the\n\ndevelopment of innovative pharmaceuticals and first-to-market generics,\n\nand has introduced an innovative anti-cancer medication Endu, a\n\nfirst-to-market medication Sinofuan, and first-to-market generics such\n\nas Bicun and Anxin. Simcere manufactures and sells anti-infective\n\nmedication, anti-cancer medication and stroke management medication.\n\nSimcere concentrates its research and development efforts on the\n\ntreatment of diseases with high incidence and/or mortality rates and for\n\nwhich there is a clear demand for more effective pharmacotherapy such as\n\ncancer, strokes, orthopaedics and infectious diseases. For more\n\ninformation about Simcere Pharmaceutical Group, please visit http://www.simcere.com.\n\nAbout Merck & Co., Inc.\n\nToday’s Merck is a global healthcare leader working to help the world be\n\nwell. Merck is known as MSD outside the United States and Canada.\n\nThrough our prescription medicines, vaccines, biologic therapies, and\n\nconsumer care and animal health products, we work with customers and\n\noperate in more than 140 countries to deliver innovative health\n\nsolutions. We also demonstrate our commitment to increasing access to\n\nhealthcare through far-reaching policies, programs and partnerships. For\n\nmore information, visit www.merck.com.\n\nAbout MSD in China\n\nMSD has more than 5,000 employees, 10 regions and 20 regional offices in\n\nChina. MSD also has three manufacturing plants in China which supply\n\ninnovative medicines and medical devices to both the local and export\n\nmarkets. The facilities’ operations encompass production, packaging,\n\nmaterials management, quality assurance, engineering services and\n\nexports.\n\nChina is one of the most critical markets for Merck’s growth strategy.\n\nFollowing the completion of the global merger between Merck and\n\nSchering-Plough in 2009, Michel Vounatsos became the president of MSD in\n\nChina. MSD China reports directly to the Merck headquarter in the United\n\nStates.\n\nForward-Looking Statement\n\nThis news release includes “forward-looking statements” within the\n\nmeaning of the safe harbor provisions of the United States Private\n\nSecurities Litigation Reform Act of 1995. Such statements may include,\n\nbut are not limited to, statements about the benefits of the merger\n\nbetween Merck and Schering-Plough, including future financial and\n\noperating results, the combined company’s plans, objectives,\n\nexpectations and intentions and other statements that are not historical\n\nfacts. Such statements are based upon the current beliefs and\n\nexpectations of Merck’s management and are subject to significant risks\n\nand uncertainties. Actual results may differ from those set forth in the\n\nforward-looking statements.\n\nThe following factors, among others, could cause actual results to\n\ndiffer from those set forth in the forward-looking statements: the\n\npossibility that the expected synergies from the merger of Merck and\n\nSchering-Plough will not be realized, or will not be realized within the\n\nexpected time period; the impact of pharmaceutical industry regulation\n\nand healthcare legislation; the risk that the businesses will not be\n\nintegrated successfully; disruption from the merger making it more\n\ndifficult to maintain business and operational relationships; Merck’s\n\nability to accurately predict future market conditions; dependence on\n\nthe effectiveness of Merck’s patents and other protections for\n\ninnovative products; the risk of new and changing regulation and health\n\npolicies in the United States and internationally and the exposure to\n\nlitigation and/or regulatory actions.\n\nMerck undertakes no obligation to publicly update any forward-looking\n\nstatement, whether as a result of new information, future events or\n\notherwise. Additional factors that could cause results to differ\n\nmaterially from those described in the forward-looking statements can be\n\nfound in Merck’s 2010 Annual Report on Form 10-K and the company’s other\n\nfilings with the Securities and Exchange Commission (SEC) available at\n\nthe SEC’s Internet site (www.sec.gov).\n\nZOCOR® and COZAAR® are registered trademarks of Merck Sharp & Dohme\n\nCorp., a subsidiary of Merck & Co., Inc. RENITEC® is a\n\nregistered trademark of Merck & Co., Inc., Whitehouse Station, N.J., USA.\n\nAll other brands are trademarks of their respective owners and are\n\nnot trademarks of Merck & Co., Inc., Whitehouse Station, N.J., USA\n\nPhotos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6802925&lang=en"
    }
}